Plasma Clusterin as a Potential Biomarker for Alzheimer's Disease-A Systematic Review and Meta-analysis.

CONCLUSION: Our meta-analysis suggested no relationship between plasma clusterin levels and the diagnosis, risk, and disease severity of AD and no difference in the CSF clusterin between AD and the control groups. Overall, there is no evidence to support plasma clusterin as a biomarker of AD based on the pooled results. PMID: 31647395 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31647395?dopt=Abstract

Source: Current Alzheimer Research - October 23, 2019 Category: Neurology Authors: Shi XR, Xie BJ, Xing Y, Tang Y Tags: Curr Alzheimer Res Source Type: research